Literature DB >> 15342634

The ISG15 isopeptidase UBP43 is regulated by proteolysis via the SCFSkp2 ubiquitin ligase.

Sara Tokarz1, Catherine Berset, Janna La Rue, Kevin Friedman, Kei-Ichi Nakayama, Keiko Nakayama, Dong-Er Zhang, Stefan Lanker.   

Abstract

The Skp2 oncoprotein belongs to the family of F-box proteins that function as substrate recognition factors for SCF (Skp1, cullin, F-box protein) E3 ubiquitin-ligase complexes. Binding of the substrate to the SCFSkp2 complex catalyzes the conjugation of ubiquitin molecules to the bound substrate, resulting in multi-ubiquitination and rapid degradation by the 26 S proteasome. Using Skp2 as bait in a yeast two-hybrid screen, we have identified UBP43 as a novel substrate for Skp2. UBP43 belongs to the family of ubiquitin isopeptidases and specifically cleaves ISG15, a ubiquitin-like molecule that is induced by cellular stresses, such as type 1 interferons (IFN), nephrotoxic damage, and bacterial infection. UBP43 was originally identified as an up-regulated gene in knock-in mice expressing an acute myelogenous leukemia fusion protein, AML1-ETO, as well as in melanoma cell lines treated with IFN-beta. The phenotype of UBP43 knockout mice includes shortened life span, hypersensitivity to IFN, and neuronal damage, suggesting that tight regulation of ISG15 conjugation is critical for normal cellular function. In this study, we demonstrate that UBP43 is ubiquitinated in vivo and accumulates in cells treated with proteasome inhibitors. We also show that Skp2 promotes UBP43 ubiquitination and degradation, resulting in higher levels of ISG15 conjugates. In Skp2-/- mouse cells, levels of UBP43 are consistently up-regulated, whereas levels of ISG15 conjugates are reduced. Our results demonstrate that the SCFSkp2 is involved in controlling UBP43 protein levels and may therefore play an important role in modulating type 1 IFN signaling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15342634     DOI: 10.1074/jbc.M403189200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

Review 1.  Viral defense, carcinogenesis and ISG15: novel roles for an old ISG.

Authors:  Ian F Pitha-Rowe; Paula M Pitha
Journal:  Cytokine Growth Factor Rev       Date:  2007-08-03       Impact factor: 7.638

Review 2.  How ISG15 combats viral infection.

Authors:  Brendan T Freitas; Florine E M Scholte; Éric Bergeron; Scott D Pegan
Journal:  Virus Res       Date:  2020-05-31       Impact factor: 3.303

3.  USP18 (UBP43) Abrogates p21-Mediated Inhibition of HIV-1.

Authors:  Edmund Osei Kuffour; Kerstin Schott; Ananda Ayyappan Jaguva Vasudevan; Jessica Holler; Wolfgang A Schulz; Philipp A Lang; Karl S Lang; Baek Kim; Dieter Häussinger; Renate König; Carsten Münk
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

Review 4.  Deregulation of F-box proteins and its consequence on cancer development, progression and metastasis.

Authors:  Jinho Heo; Rebeka Eki; Tarek Abbas
Journal:  Semin Cancer Biol       Date:  2015-09-30       Impact factor: 15.707

5.  Approaches for investigating the extracellular signaling function of ISG15.

Authors:  Caleb D Swaim; Larissa A Canadeo; Jon M Huibregtse
Journal:  Methods Enzymol       Date:  2019-02-01       Impact factor: 1.600

Review 6.  Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions.

Authors:  Joana Loureiro; Hidde L Ploegh
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

7.  Global changes in STAT target selection and transcription regulation upon interferon treatments.

Authors:  Stephen E Hartman; Paul Bertone; Anjali K Nath; Thomas E Royce; Mark Gerstein; Sherman Weissman; Michael Snyder
Journal:  Genes Dev       Date:  2005-11-30       Impact factor: 11.361

Review 8.  Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer.

Authors:  David Frescas; Michele Pagano
Journal:  Nat Rev Cancer       Date:  2008-06       Impact factor: 60.716

Review 9.  The Skp2 Pathway: A Critical Target for Cancer Therapy.

Authors:  Zhen Cai; Asad Moten; Danni Peng; Che-Chia Hsu; Bo-Syong Pan; Rajeshkumar Manne; Hong-Yu Li; Hui-Kuan Lin
Journal:  Semin Cancer Biol       Date:  2020-02-01       Impact factor: 17.012

10.  Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation.

Authors:  Xianqin Zhang; Dusan Bogunovic; Béatrice Payelle-Brogard; Véronique Francois-Newton; Scott D Speer; Chao Yuan; Stefano Volpi; Zhi Li; Ozden Sanal; Davood Mansouri; Ilhan Tezcan; Gillian I Rice; Chunyuan Chen; Nahal Mansouri; Seyed Alireza Mahdaviani; Yuval Itan; Bertrand Boisson; Satoshi Okada; Lu Zeng; Xing Wang; Hui Jiang; Wenqiang Liu; Tiantian Han; Delin Liu; Tao Ma; Bo Wang; Mugen Liu; Jing-Yu Liu; Qing K Wang; Dilek Yalnizoglu; Lilliana Radoshevich; Gilles Uzé; Philippe Gros; Flore Rozenberg; Shen-Ying Zhang; Emmanuelle Jouanguy; Jacinta Bustamante; Adolfo García-Sastre; Laurent Abel; Pierre Lebon; Luigi D Notarangelo; Yanick J Crow; Stéphanie Boisson-Dupuis; Jean-Laurent Casanova; Sandra Pellegrini
Journal:  Nature       Date:  2014-10-12       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.